Search
Xeris Biopharma Holdings Inc
XERSAdd to Watchlist
10.130USD
+1.050+11.56%
Close 10-05 16:00（ET）
1.75BMarket Cap
131.64P/E TTM
After-hours 16:45 (ET)10.110USD-0.015-0.15%
After-hours 16:45 (ET)Xeris Biopharma Holdings Inc (XERS) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Xeris Biopharma Holdings Inc in the past month.
Buy
3 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
12.286USD+35.31%
XERS Analyst Recommendation Trends
In the current month, XERS has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. XERS average Analyst price target in the last month is 12.286.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
7
7
7
7
XERS Analyst Rating for Peer Comparison
Updated: Oct 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
15
10
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, XERS EPS is projected to reach 0.028 in FY2026Q3, following reported EPS of -0.180 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.04
-0.01
0.00
0.03
0.04
Actual
0.07
0.01
-0.18
--
--
Surprise
+51.68%
+257.26%
-5504.20%
--
--
FAQs
What is Xeris Biopharma Holdings Inc's expected revenue for the next quarter?
Xeris Biopharma Holdings Inc's expected revenue is 101.47M.
What is Xeris Biopharma Holdings Inc's price target?
Analysts forecast that Xeris Biopharma Holdings Inc's price target is USD 12.29, with the highest forecast at USD 18.00 and the lowest forecast at USD 8.00.
How have Xeris Biopharma Holdings IncXERS's recent earnings per share performed?
The market expectation was USD -0.18, while Xeris Biopharma Holdings IncXERS's earnings per share (EPS) for the previous quarter was USD 0.01. EPS for the next quarter is expected at USD 0.03.
What is the analyst rating for Xeris Biopharma Holdings Inc?
Based on the ratings of Xeris Biopharma Holdings Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.